Active Invest Sweden

Active Biotech is a Swedish biotechnology company focused on the development of specialized immunotherapies for the treatment of cancer and inflammatory diseases. The company's clinical-stage pipeline is centered on three lead assets: tasquinimod, laquinimod, and naptumomab. Tasquinimod is an oral small molecule targeting the S100A9 protein, currently being evaluated in Phase 2 trials for multiple myeloma and myelofibrosis. Laquinimod is a small molecule immunomodulator being developed for the treatment of inflammatory eye diseases, specifically non-infectious uveitis. Active Biotech also partners with NeoTX for the development of naptumomab, a tumor-targeting fusion protein designed to redirect immune cells to 5T4-expressing solid tumors.